Open-label Adalimumab
Phase 3Monoclonal antibody
AbbVieOpen-label Adalimumab is one of 53 biologic programs targeting Arthritis. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Actemra
RochePreclinical
Enbrel
IImmunex
Preclinical
Remicade
OOrganon and Co
Preclinical
Open-label Adalimumab
AbbViePhase 3
Actos
TakedaPreclinical
Kineret
SSwedish Orphan Biovitrum
Preclinical
Velcade
SShilpa Grover, MD, MPH
Preclinical
Vancocin
HHikma Pharmaceuticals LLC
Preclinical
Cimzia
UCBPreclinical
Circadin
NNeurim Pharmaceuticals Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Open-label Adalimumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]